Iambic Therapeutics, Inc.
Iambic Therapeutics filed Amendment No. 1 to its S-1 registration for an IPO on Nasdaq under ticker "IAM." The offering comprises 9,375,000 shares at an expected price range of $15.00 to $17.00 per share, implying gross proceeds of approximately $140.6M to $159.4M before the 1,406,250-share greenshoe option. ARK Investment Management and Duquesne Family Office have expressed non-binding indications of interest for up to $60.0M of the offering.
- Offering 9,375,000 shares at $15.00–$17.00 per share, targeting up to ~$159.4M in gross proceeds before the greenshoe.
- ARK Investment Management and Duquesne Family Office indicated interest in purchasing up to $60.0M of the offering.
- Lead asset IAM1363 (HER2 inhibitor) is in a Phase 1/1b trial; registrational trial anticipated as early as 2027.
- IND submitted for IAM217 (KIF18A inhibitor) on September 30, 2026; IND for IAM-C1 (CDK2/4 inhibitor) expected Q4 2026.
- Raised ~$461.8M in private capital since inception; partnerships include AbbVie, Takeda, Bayer, and Revolution Medicines.
Price data unavailable.
A well-capitalized ($462M raised) AI-native drug discovery platform is testing public markets with three clinical-stage catalysts within 12 months and notable anchor-investor demand.
Joins a wave of AI-native biotech IPOs (Recursion, Absci, Exscientia) seeking to validate platform-driven drug discovery. The $60M insider demand signal from ARK and Duquesne mirrors the anchor-investor trend seen in recent biotech listings.
No approved drug products; platform is novel and unproven. All pipeline assets are preclinical or early clinical. Heavy reliance on AI-driven discovery that may not translate to clinical success. "Emerging growth company" with limited public-company operating history.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.